Biovie Inc (BIVI) Peer Comparison
$2.17
$-0.03
(-1.14%)
As on 28-Aug-2026 13:38EDT
Market cap
$16 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Edit
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
16 | 17,326 | 16,614 | 13,400 | 12,305 |
Revenue ($ Mln) |
-- | 2,782 | 1,054 | 2,436 | 670 |
Net Profit ($ Mln) |
-22.07 | 491.50 | 755.85 | 860.62 | -319.95 |
Net Margin (%) |
-- | 17.67 | 71.69 | 35.33 | -47.79 |
RoE (%) |
0.00 | 110.09 | -- | 42.98 | -71.14 |
Price to Earnings |
-- | 36.49 | 19.38 | 17.01 | -- |
Price-To-Book |
1.53 | 39.43 | 10.05 | 7.27 | 26.44 |
Income Statement ($ Mln)
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
-- | -- | -- | -- | -- |
|
Cost of Revenue
|
-- | -- | -- | -- | -- |
|
Gross Profit
|
-- | -- | -- | -- | -- |
|
Operating Expenses
|
22.65 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
-22.65 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-22.07 | -- | -- | -- | -- |
|
Provision for Tax
|
-- | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
-22.07 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
10,270,270.00 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
184,421.00 | -- | -- | -- | -- |
|
Current Liabilities
|
3,795,771.00 | -- | -- | -- | -- |
|
Total Liabilities
|
14,250,462.00 | -- | -- | -- | -- |
Assets ($ Mln)
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
608,297.00 | -- | -- | -- | -- |
|
Current Assets
|
13,642,165.00 | -- | -- | -- | -- |
|
Total Assets
|
14,250,462.00 | -- | -- | -- | -- |
|
Total Debt*
|
275,430.00 | -- | -- | -- | -- |
|
Net Current Assets
|
-- | -- | -- | -- | -- |
Cashflow ($ Mln)
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-19,024.81 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-- | -- | -- | -- | -- |
|
Cash from Financing Activities
|
10,457.63 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
0.00 | -- | -- | -- | -- |
|
ROE (%)
|
0.00 | -- | -- | -- | -- |
|
ROA (%)
|
0.00 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-25.83 | -- | -- | -- | -- |
|
EPS Growth (%)
|
-1.46 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.66 | -- | -- | -- | -- |
|
Price / Book Value
|
0.00 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
397,772.83 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.03 | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
0.01 | -- | -- | -- | -- |
|
Current Ratio
|
3.59 | -- | -- | -- | -- |
|
Quick Ratio
|
-- | -- | -- | -- | -- |
|
Interest Coverage
|
-1,232.05 | -- | -- | -- | -- |
Operating Efficiency Ratios
| Biovie Inc (BIVI) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | -- | -- | -- |
|
Asset Turnover
|
-- | -- | -- | -- | -- |
|
Receivable days
|
-- | -- | -- | -- | -- |
|
Inventory Days
|
-- | -- | -- | -- | -- |
|
Payable days
|
-- | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
-- | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
